Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 92.2% in January

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 154,900 shares, an increase of 92.2% from the January 15th total of 80,600 shares. Currently, 8.9% of the shares of the stock are sold short. Based on an average trading volume of 366,900 shares, the days-to-cover ratio is currently 0.4 days.

Avenue Therapeutics Stock Performance

Shares of NASDAQ:ATXI opened at $1.32 on Thursday. Avenue Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $15.00. The firm has a fifty day moving average price of $1.72 and a 200 day moving average price of $2.14. The firm has a market cap of $2.71 million, a price-to-earnings ratio of 0.07 and a beta of -0.28.

Hedge Funds Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.